Immune-mediated lung injury plays a pivotal role in severe interstitial pnemumonia related to
SARS-CoV2 infection. Tofacitinib, a JAK1/3-Inhibitor, could mitigate alveolar inflammation by
blocking IL-6 signal. The aim of this prospective single cohort open study is to test the
hypotesis that early administration of tofacitinib in patients with symptomatic pneumonia
could reduce pulmonary flogosis, preventing function deterioration and the need of mechanical
ventilation and/or admission in intensive care units.